Tags: 
Patients with mild COVID 19 infection, from a variety of age groups, were still experiencing major symptoms for months after COVID 19 disease is over.
Read full article: https://jamanetwork.com/journals/jama/fullarticle/2768351
The Jama study was conducted in 143 COVID 19 patients. The mean age was 56.5 (SD, 14.6) years (range, 19-84 years), and 53 (37%) were women. During hospitalization, 72.7% of participants had evidence of interstitial pneumonia. The mean length of hospital stay was 13.5 (SD, 9.7) days; 21 patients (15%) received noninvasive ventilation and 7 patients (5%) received invasive ventilation.
It was reported that ~60.3 days after onset of the first COVID-19 symptom; 32% of patients had 1 or 2 symptoms and 55% had 3 or more. None of the patients had symptoms of acute disease. Worsened quality of life was observed among 44.1% of patients. The Figure shows that a high proportion of individuals still reported fatigue (53.1%), dyspnea (43.4%), joint pain, (27.3%) and chest pain (21.7%) and worsened quality of life (44.1%) of patients.
These data have been confirmed by other reports that showed Covid-19 long-term impacts on the lungs, heart, immune system, and even the brain which may drive an increase of pathologies in these organs.
COVID 19 therapies in development should prove effects on the acute disease as well as long-term symptoms on target organs.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.